Prelude Therapeutics (PRLD) Capital Expenditures (QoQ) (2020 - 2025)
Prelude Therapeutics (PRLD) Capital Expenditures (QoQ) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -57.45% |
| Mar 31, 2025 | 106.70% |
| Dec 31, 2024 | -1,212.70% |
| Sep 30, 2024 | -82.45% |
| Jun 30, 2024 | 24.22% |
| Mar 31, 2024 | -74.40% |
| Dec 31, 2023 | 91.03% |
| Sep 30, 2023 | -39.88% |
| Jun 30, 2023 | 21.36% |
| Mar 31, 2023 | 447.64% |
| Dec 31, 2022 | 83.20% |
| Sep 30, 2022 | -202.29% |
| Jun 30, 2022 | 283.05% |
| Mar 31, 2022 | 129.02% |
| Dec 31, 2021 | -174.39% |
| Sep 30, 2021 | 373.33% |
| Jun 30, 2021 | -160.85% |
| Mar 31, 2021 | 108.46% |
| Dec 31, 2020 | 178.24% |
| Sep 30, 2020 | 91.01% |